News
FTRE
14.47
-0.96%
-0.14
Fortrea Holdings Price Target Raised to $13.00/Share From $11.00 by Mizuho
Dow Jones · 2d ago
Fortrea Holdings Is Maintained at Neutral by Mizuho
Dow Jones · 2d ago
Mizuho Maintains Neutral on Fortrea Holdings, Raises Price Target to $13
Benzinga · 2d ago
Fortrea price target raised to $13 from $11 at Mizuho
TipRanks · 2d ago
Weekly Report: what happened at FTRE last week (0504-0508)?
Weekly Report · 3d ago
Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine
Seeking Alpha · 5d ago
Fortrea price target raised to $14 from $11 at Deutsche Bank
TipRanks · 6d ago
Is It Too Late To Consider Fortrea Holdings (FTRE) After Its Recent Share Price Surge?
Simply Wall St · 6d ago
Fortrea price target raised to $16 from $11 at Barclays
TipRanks · 05/07 10:25
Fortrea price target raised to $20 from $15 at Baird
TipRanks · 05/07 09:20
Fortrea price target raised to $20 from $16 at Citi
TipRanks · 05/07 08:48
Fortrea Holdings Price Target Raised to $20.00/Share From $16.00 by Citigroup
Dow Jones · 05/06 19:34
Fortrea Holdings Is Maintained at Buy by Citigroup
Dow Jones · 05/06 19:34
Citigroup Maintains Buy on Fortrea Holdings, Raises Price Target to $20
Benzinga · 05/06 19:25
Fortrea Holdings Price Target Raised to $16.00/Share From $11.00 by Barclays
Dow Jones · 05/06 15:07
Fortrea Holdings Is Maintained at Equal-Weight by Barclays
Dow Jones · 05/06 15:07
Barclays Maintains Equal-Weight on Fortrea Holdings, Raises Price Target to $16
Benzinga · 05/06 14:57
Bank of America Securities Keeps Their Sell Rating on Fortrea Holdings Inc. (FTRE)
TipRanks · 05/06 10:37
FORTREA <FTRE.O>: BOFA GLOBAL RESEARCH RAISES PRICE OBJECTIVE TO $9.50 FROM $8.00
Reuters · 05/06 10:14
Barclays Reaffirms Their Hold Rating on Fortrea Holdings Inc. (FTRE)
TipRanks · 05/06 08:27
More
Webull provides a variety of real-time FTRE stock news. You can receive the latest news about Fortrea Holdings through multiple platforms. This information may help you make smarter investment decisions.
About FTRE
Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.